Oncology & Cancer

FDA: Cyramza approval now includes non-small-cell lung CA

(HealthDay)—U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Oncology & Cancer

Botox for stomach cancer? No, but the research is fascinating

Amid continuing tales of global woe, Thursday morning's news carried one of those quirky 'fancy-that!' medical research stories that often captures the imagination, but which can inadvertently raise false hope in patients.

Oncology & Cancer

New view of stomach cancer could hasten better therapies

In a massive effort to catalog the molecular causes of stomach cancer, scientists, including researchers at Dana-Farber Cancer Institute, have identified four subtypes of tumors based on shared mutations and other molecular ...

page 11 from 16